Investment Thesis
Aura Biosciences is a pre-revenue biotech company with significant cash burn (-$64.3M operating cash flow) and no commercial revenue generation. While the company maintains strong liquidity with $47.6M cash and low leverage, the current burn rate at existing cash levels suggests limited runway without additional financing or achieving major clinical milestones. The absence of revenue combined with substantial operating losses and negative ROE/ROA indicates the company is in early-stage development with substantial execution risk.
Strengths
- Strong liquidity position with $47.6M cash and 9.04x current ratio providing near-term financial flexibility
- Zero debt burden with minimal financial leverage, reducing refinancing risk
- Reasonable equity base of $156.7M providing capital cushion for development activities
Risks
- No revenue generation with significant operating losses of -$85.6M indicating company is pre-commercial
- Severe cash burn of -$64.3M annually suggests limited runway of approximately 9 months at current burn rates without additional financing
- Biotech development risk: No evidence of approved products or positive clinical trial outcomes; success depends entirely on R&D execution and regulatory approval
Key Metrics to Watch
- Cash runway and path to profitability or next major financing event
- Clinical trial progress and regulatory milestones for lead programs
- Operating cash burn rate trends and any revenue-generating product approvals
Financial Metrics
Revenue
N/A
Net Income
-80.6M
EPS (Diluted)
$-1.39
Free Cash Flow
-64.5M
Total Assets
190.0M
Cash
47.6M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-51.5%
ROA
-42.4%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
9.04x
Quick Ratio
9.04x
Debt/Equity
0.00x
Debt/Assets
17.6%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-20T10:18:11.294491 |
Data as of: 2025-09-30 |
Powered by Claude AI